查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1625468

难治性痛风市场规模、占有率、趋势、行业分析报告（按治疗类型、分销管道和地区）- 市场预测，2025-2034 年

Refractory Gout Market Size, Share, Trends, Industry Analysis Report: By Treatment Type, Distribution Channel, and Region - Market Forecast, 2025-2034
出版日期: | 出版商: Polaris Market Research | 英文 117 Pages | 商品交期: 最快1-2个工作天内

价格

根据Polaris Market Research的最新研究，到2034年全球痛风市场规模预计将达到15.9924亿美元。该研究报告对当前市场动态提供了详细的见解，并对未来市场成长进行了分析。

由于对常规治疗没有反应的严重痛风病例数量不断增加，难治性痛风市场正在稳步扩大。难治性痛风的特征是儘管接受了标准治疗，症状仍会持续存在，需要先进的治疗方法，这是推动市场成长的主要因素。市场分为生物疗法和非生物疗法，其中生物疗法由于其针对性作用和在治疗复杂病例方面的高效性而占据了显着的市场占有率。这些治疗方法包括单株抗体和酵素抑制剂，越来越受欢迎，刺激了市场需求并促进了市场扩张。

医疗保健专业人员和患者对创新治疗方案可用性的认识不断提高也是推动市场规模的关键因素。医院和专科诊所是治疗难治性痛风的主要机构，提供先进的治疗和专业的护理，在市场成长中发挥关键作用。随着生物製剂的应用日益广泛和专业设施的普及，该行业预计将显着增长。

技术的进步、持续的研究和开发以及新药的批准进一步加强了难治性痛风市场。此外，老年人口的不断增长，使他们更容易患上严重的痛风，这也促使市场需求的增加。旨在改善获得先进治疗机会的有利政府措施和医疗政策也支持了市场扩张。

难治性痛风市场报告重点

根据治疗类型，生物製剂由于其广泛的应用范围和在症状管理方面的有效性，在难治性痛风市场中占据主要市场占有率。

根据分销管道，预计预测期内治疗严重复杂病例的医院和专科诊所将显着增长。

由于北美拥有先进的医疗基础设施和高痛风盛行率，因此占难治性痛风市场的最大占有率。

由于新兴经济体医疗保健投资的增加以及人们对痛风管理的认识的不断提高，预计亚太地区将在预测期内出现显着增长。

目录

第 1 章简介

第 2 章执行摘要

第 3 章 研究方法

第 4 章全球难治性痛风市场洞察

  • 市场概况
  • 难治性痛风市场动态
    • 推动因素和机遇
      • 治疗难治性痛风的生物製剂需求不断增加
      • 越来越重视个人化医疗和基因检测
    • 阻碍因素和课题
      • 医疗费用高昂
  • PESTEL 分析
  • 难治性痛风市场的应用趋势
  • 价值链分析
  • COVID-19 影响分析

第 5 章全球难治性痛风市场（依治疗类型划分）
  • 主要发现
  • 简介
  • 生物治疗
  • 非生物治疗

第6章 全球难治性痛风市场依通路划分

  • 主要发现
  • 简介
  • 医院和专科诊所
  • 零售药局
  • 网路药局

第7章 全球难治性痛风市场（按地区）

  • 主要发现
  • 简介
    • 难治性痛风市场评估：各地区，2020 年至 2034 年
  • 北美洲
    • 2020 年至 2034 年，北美依治疗类型划分
    • 2020 年至 2034 年，北美依通路划分
    • 美国
    • 加拿大
  • 欧洲
      2020 年至 2034 年欧洲依治疗类型划分 2020 年至 2034 年欧洲按通路划分
    • 英国
    • 法国
    • 德国
    • 义大利
    • 西班牙
    • 荷兰
    • 俄罗斯
    • 其他欧洲国家
    亚太地区
      亚太地区，依治疗类型，2020 年至 2034 年 2020 年至 2034 年亚太地区通路分布
    • 中国
    • 印度
    • 马来西亚
    • 日本
    • 印尼
    • 韩国
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲
      中东和非洲：依治疗类型，2020 年至 2034 年 2020 年至 2034 年中东和非洲按分销管道划分
    • 沙乌地阿拉伯
    • 阿拉伯联合大公国
    • 以色列
    • 南非
    • 其他中东和非洲地区
  • 拉丁美洲
    • 拉丁美洲，依治疗类型，2020 年至 2034 年
    • 2020 年至 2034 年拉丁美洲依通路划分
    • 墨西哥
    • 巴西
    • 阿根廷
    • 其他拉丁美洲国家

第 8 章 竞争格局

  • 扩张与收购分析
    • 放大
    • 收购
  • 伙伴关係/协作/协定/揭露

第9章 公司简介

  • Horizon Therapeutics
  • Novartis AG
  • Takeda Pharmaceuticals
  • Grifols, S.A.
  • Ironwood Pharmaceuticals
  • Selecta Biosciences
  • Teijin Pharma
  • Pfizer Inc.
  • Sobi（Swedish Orphan Biovitrum）
  • LG Chem
  • AstraZeneca
  • Mylan N.V.
  • Sanofi
  • GlaxoSmithKline plc（GSK）
  • Ardea Biosciences
Product Code: PM5327

The global refractory gout market size is expected to reach USD 1,599.24 million by 2034, according to a new study by Polaris Market Research. The report "Refractory Gout Market Size, Share, Trends, Industry Analysis Report: By Treatment Type (Biological and Non-Biological Treatments), Distribution Channel, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The refractory gout market is witnessing steady expansion, driven by the increasing prevalence of severe gout cases unresponsive to conventional therapies. Refractory gout, characterized by persistent symptoms despite standard treatment, requires advanced therapeutic approaches, which significantly contribute to market growth. The market is segmented into biological and non-biological treatments, with biological therapies gaining notable market share due to their targeted action and higher efficacy in managing complex cases. These treatments, which include monoclonal antibodies and enzyme inhibitors, are increasingly favored, boosting market demand and fostering market expansion.

The rising awareness among healthcare professionals and patients about the availability of innovative treatment options is another crucial factor driving market size. Hospitals and specialty clinics, as primary treatment providers for refractory gout, play a pivotal role in market growth by offering access to advanced therapies and expert care. This segment is expected to witness significant growth, supported by the increasing adoption of biologics and the availability of specialized facilities.

Technological advancements, ongoing research and development, and the approval of novel drugs are further enhancing the refractory gout market. Additionally, the growing geriatric population, which is more susceptible to severe gout, is contributing to the increasing market demand. Favorable government initiatives and healthcare policies aimed at improving access to advanced treatments also support market expansion.

Refractory Gout Market Report Highlights:

In terms of treatment type, the biological treatment segment holds the significant market share in the refractory gout market due to their broad application and efficacy in managing symptoms.

By distribution channel, the hospitals and specialty clinics segment is expected to witness significant growth over the forecast period, driven by their capacity to handle severe and complex cases.

North America holds the largest share of the refractory gout market, with its advanced healthcare infrastructure and high prevalence of gout.

Asia Pacific is expected to witness significant growth over the forecast period, owing to increasing healthcare investments and rising awareness of gout management in emerging economies.

Polaris Market Research has segmented the refractory gout market report on the basis of treatment type, distribution channel, and region:

By Treatment Type Outlook (Revenue USD Million, 2020-2034)

  • Biologics
  • Pegloticase (Krystexxa)
  • Canakinumab
  • Non-Biologics
  • NSAIDs
  • Corticosteroids
  • Colchicine
  • Uricosurics (e.g., probenecid)

By Distribution Channel Outlook (Revenue USD Million, 2020-2034)

  • Hospitals and Specialty Clinics
  • Retail Pharmacies
  • Online Pharmacies

By Regional Outlook (Revenue USD Million, 2020-2034)

  • North America
  • US
  • Canada
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Netherlands
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • Malaysia
  • South Korea
  • Indonesia
  • Australia
  • Vietnam
  • Rest of Asia Pacific
  • Middle East & Africa
  • Saudi Arabia
  • UAE
  • Israel
  • South Africa
  • Rest of Middle East & Africa
  • Latin America
  • Mexico
  • Brazil
  • Argentina
  • Rest of Latin America

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Refractory Gout Market Insights

  • 4.1. Refractory Gout Market - Market Snapshot
  • 4.2. Refractory Gout Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Rising Demand for Biologics in Refractory Gout Treatment
      • 4.2.1.2. Surging Focus on Personalized Medicine and Genetic Testing
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High Treatment Costs
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Refractory Gout Market Application Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Refractory Gout Market, by Treatment Type

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
  • 5.3. Biologics
    • 5.3.1. Global Refractory Gout Market, by Biologics, by Region, 2020-2034 (USD Million)
    • 5.3.2. Pegloticase (Krystexxa)
      • 5.3.2.1. Global Refractory Gout Market, by Pegloticase (Krystexxa), by Region, 2020-2034 (USD Million)
    • 5.3.3. Canakinumab
      • 5.3.3.1. Global Refractory Gout Market, by Canakinumab, by Region, 2020-2034 (USD Million)
  • 5.4. Non-Biologics
    • 5.4.1. Global Refractory Gout Market, by Non-Biologics, by Region, 2020-2034 (USD Million)
    • 5.4.2. NSAIDs
      • 5.4.2.1. Global Refractory Gout Market, by NSAIDs, by Region, 2020-2034 (USD Million)
    • 5.4.3. Corticosteroids
      • 5.4.3.1. Global Refractory Gout Market, by Corticosteroids, by Region, 2020-2034 (USD Million)
    • 5.4.4. Colchicine
      • 5.4.4.1. Global Refractory Gout Market, by Colchicine, by Region, 2020-2034 (USD Million)
    • 5.4.5. Uricosurics (e.g., probenecid)
      • 5.4.5.1. Global Refractory Gout Market, by Uricosurics (e.g., probenecid), by Region, 2020-2034 (USD Million)

6. Global Refractory Gout Market, by Distribution Channel

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
  • 6.3. Hospitals and Specialty Clinics
    • 6.3.1. Global Refractory Gout Market, by Hospitals and Specialty Clinics, by Region, 2020-2034 (USD Million)
  • 6.4. Retail Pharmacies
    • 6.4.1. Global Refractory Gout Market, by Retail Pharmacies, by Region, 2020-2034 (USD Million)
  • 6.5. Online Pharmacies
    • 6.5.1. Global Refractory Gout Market, by Online Pharmacies, by Region, 2020-2034 (USD Million)

7. Global Refractory Gout Market, by Geography

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Refractory Gout Market Assessment, By Geography, 2020-2034 (USD Million)
  • 7.3. Refractory Gout Market - North America
    • 7.3.1. North America: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
    • 7.3.2. North America: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
    • 7.3.3. Refractory Gout Market - US
      • 7.3.3.1. US: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.3.3.2. US: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
    • 7.3.4. Refractory Gout Market - Canada
      • 7.3.4.1. Canada: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.3.4.2. Canada: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
  • 7.4. Refractory Gout Market - Europe
    • 7.4.1. Europe: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
    • 7.4.2. Europe: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
    • 7.4.3. Refractory Gout Market - UK
      • 7.4.3.1. UK: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.4.3.2. UK: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
    • 7.4.4. Refractory Gout Market - France
      • 7.4.4.1. France: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.4.4.2. France: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
    • 7.4.5. Refractory Gout Market - Germany
      • 7.4.5.1. Germany: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.4.5.2. Germany: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
    • 7.4.6. Refractory Gout Market - Italy
      • 7.4.6.1. Italy: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.4.6.2. Italy: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
    • 7.4.7. Refractory Gout Market - Spain
      • 7.4.7.1. Spain: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.4.7.2. Spain: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
    • 7.4.8. Refractory Gout Market - Netherlands
      • 7.4.8.1. Netherlands: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.4.8.2. Netherlands: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
    • 7.4.9. Refractory Gout Market - Russia
      • 7.4.9.1. Russia: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.4.9.2. Russia: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
    • 7.4.10. Refractory Gout Market - Rest of Europe
      • 7.4.10.1. Rest of Europe: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.4.10.2. Rest of Europe: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
  • 7.5. Refractory Gout Market - Asia Pacific
    • 7.5.1. Asia Pacific: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
    • 7.5.2. Asia Pacific: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
    • 7.5.3. Refractory Gout Market - China
      • 7.5.3.1. China: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.5.3.2. China: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
    • 7.5.4. Refractory Gout Market - India
      • 7.5.4.1. India: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.5.4.2. India: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
    • 7.5.5. Refractory Gout Market - Malaysia
      • 7.5.5.1. Malaysia: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.5.5.2. Malaysia: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
    • 7.5.6. Refractory Gout Market - Japan
      • 7.5.6.1. Japan: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.5.6.2. Japan: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
    • 7.5.7. Refractory Gout Market - Indonesia
      • 7.5.7.1. Indonesia: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.5.7.2. Indonesia: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
    • 7.5.8. Refractory Gout Market - South Korea
      • 7.5.8.1. South Korea: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.5.8.2. South Korea: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
    • 7.5.9. Refractory Gout Market - Australia
      • 7.5.9.1. Australia: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.5.9.2. Australia: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
    • 7.5.10. Refractory Gout Market - Rest of Asia Pacific
      • 7.5.10.1. Rest of Asia Pacific: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.5.10.2. Rest of Asia Pacific: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
  • 7.6. Refractory Gout Market - Middle East & Africa
    • 7.6.1. Middle East & Africa: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
    • 7.6.2. Middle East & Africa: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
    • 7.6.3. Refractory Gout Market - Saudi Arabia
      • 7.6.3.1. Saudi Arabia: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.6.3.2. Saudi Arabia: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
    • 7.6.4. Refractory Gout Market - UAE
      • 7.6.4.1. UAE: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.6.4.2. UAE: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
    • 7.6.5. Refractory Gout Market - Israel
      • 7.6.5.1. Israel: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.6.5.2. Israel: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
    • 7.6.6. Refractory Gout Market - South Africa
      • 7.6.6.1. South Africa: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.6.6.2. South Africa: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
    • 7.6.7. Refractory Gout Market - Rest of Middle East & Africa
      • 7.6.7.1. Rest of Middle East & Africa: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.6.7.2. Rest of Middle East & Africa: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
  • 7.7. Refractory Gout Market - Latin America
    • 7.7.1. Latin America: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
    • 7.7.2. Latin America: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
    • 7.7.3. Refractory Gout Market - Mexico
      • 7.7.3.1. Mexico: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.7.3.2. Mexico: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
    • 7.7.4. Refractory Gout Market - Brazil
      • 7.7.4.1. Brazil: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.7.4.2. Brazil: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
    • 7.7.5. Refractory Gout Market - Argentina
      • 7.7.5.1. Argentina: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.7.5.2. Argentina: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
    • 7.7.6. Refractory Gout Market - Rest of Latin America
      • 7.7.6.1. Rest of Latin America: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.7.6.2. Rest of Latin America: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

8. Competitive Landscape

  • 8.1. Expansion and Acquisition Analysis
    • 8.1.1. Expansion
    • 8.1.2. Acquisitions
  • 8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

  • 9.1. Horizon Therapeutics
    • 9.1.1. Company Overview
    • 9.1.2. Financial Performance
    • 9.1.3. Product Benchmarking
    • 9.1.4. Recent Development
  • 9.2. Novartis AG
    • 9.2.1. Company Overview
    • 9.2.2. Financial Performance
    • 9.2.3. Product Benchmarking
    • 9.2.4. Recent Development
  • 9.3. Takeda Pharmaceuticals
    • 9.3.1. Company Overview
    • 9.3.2. Financial Performance
    • 9.3.3. Product Benchmarking
    • 9.3.4. Recent Development
  • 9.4. Grifols, S.A.
    • 9.4.1. Company Overview
    • 9.4.2. Financial Performance
    • 9.4.3. Product Benchmarking
    • 9.4.4. Recent Development
  • 9.5. Ironwood Pharmaceuticals
    • 9.5.1. Company Overview
    • 9.5.2. Financial Performance
    • 9.5.3. Product Benchmarking
    • 9.5.4. Recent Development
  • 9.6. Selecta Biosciences
    • 9.6.1. Company Overview
    • 9.6.2. Financial Performance
    • 9.6.3. Product Benchmarking
    • 9.6.4. Recent Development
  • 9.7. Teijin Pharma
    • 9.7.1. Company Overview
    • 9.7.2. Financial Performance
    • 9.7.3. Product Benchmarking
    • 9.7.4. Recent Development
  • 9.8. Pfizer Inc.
    • 9.8.1. Company Overview
    • 9.8.2. Financial Performance
    • 9.8.3. Product Benchmarking
    • 9.8.4. Recent Development
  • 9.9. Sobi (Swedish Orphan Biovitrum)
    • 9.9.1. Company Overview
    • 9.9.2. Financial Performance
    • 9.9.3. Product Benchmarking
    • 9.9.4. Recent Development
  • 9.10. LG Chem
    • 9.10.1. Company Overview
    • 9.10.2. Financial Performance
    • 9.10.3. Product Benchmarking
    • 9.10.4. Recent Development
  • 9.11. AstraZeneca
    • 9.11.1. Company Overview
    • 9.11.2. Financial Performance
    • 9.11.3. Product Benchmarking
    • 9.11.4. Recent Development
  • 9.12. Mylan N.V.
    • 9.12.1. Company Overview
    • 9.12.2. Financial Performance
    • 9.12.3. Product Benchmarking
    • 9.12.4. Recent Development
  • 9.13. Sanofi
    • 9.13.1. Company Overview
    • 9.13.2. Financial Performance
    • 9.13.3. Product Benchmarking
    • 9.13.4. Recent Development
  • 9.14. GlaxoSmithKline plc (GSK)
    • 9.14.1. Company Overview
    • 9.14.2. Financial Performance
    • 9.14.3. Product Benchmarking
    • 9.14.4. Recent Development
  • 9.15. Ardea Biosciences
    • 9.15.1. Company Overview
    • 9.15.2. Financial Performance
    • 9.15.3. Product Benchmarking
    • 9.15.4. Recent Development

List of Tables:

Table 1 Global Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 2 Global Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 3 North America: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 4 North America: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 5 US: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 6 US: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 7 Canada: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 8 Canada: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 9 Europe: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 10 Europe: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 11 UK: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 12 UK: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 13 France: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 14 France: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 15 Germany: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 16 Germany: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 17 Italy: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 18 Italy: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 19 Spain: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 20 Spain: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 21 Netherlands: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 22 Netherlands: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 23 Russia: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 24 Russia: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 25 Rest of Europe: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 26 Rest of Europe: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 27 Asia Pacific: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 28 Asia Pacific: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 29 China: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 30 China: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 31 India: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 32 India: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 33 Malaysia: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 34 Malaysia: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 35 Japan: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 36 Japan: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 37 Indonesia: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 38 Indonesia: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 39 South Korea: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 40 South Korea: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 41 Australia: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 42 Australia: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 43 Rest of Asia Pacific: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 44 Rest of Asia Pacific: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 45 Middle East & Africa: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 46 Middle East & Africa: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 47 Saudi Arabia: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 48 Saudi Arabia: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 49 UAE: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 50 UAE: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 51 Israel: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 52 Israel: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 53 South Africa: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 54 South Africa: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 55 Rest of Middle East & Africa: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 56 Rest of Middle East & Africa: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 57 Latin America: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 58 Latin America: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 59 Mexico: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 60 Mexico: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 61 Brazil: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 62 Brazil: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 63 Argentina: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 64 Argentina: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 65 Rest of Latin America: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 66 Rest of Latin America: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

List of Figures:

Figure 1. Global Refractory Gout Market, 2020-2034 (USD Million)

Figure 2. Integrated Ecosystem

Figure 3. Research Methodology: Top-Down & Bottom-Up Price

Figure 4. Market by Geography

Figure 5. Porter's Five Forces

Figure 6. Market by Treatment Type

Figure 7. Global Refractory Gout Market, by Treatment Type, 2024 & 2034 (USD Million)

Figure 8. Market by Distribution Channel

Figure 9. Global Refractory Gout Market, by Distribution Channel, 2024 & 2034 (USD Million)